propranolol has been researched along with Cognition Disorders in 13 studies
Propranolol: A widely used non-cardioselective beta-adrenergic antagonist. Propranolol has been used for MYOCARDIAL INFARCTION; ARRHYTHMIA; ANGINA PECTORIS; HYPERTENSION; HYPERTHYROIDISM; MIGRAINE; PHEOCHROMOCYTOMA; and ANXIETY but adverse effects instigate replacement by newer drugs.
propranolol : A propanolamine that is propan-2-ol substituted by a propan-2-ylamino group at position 1 and a naphthalen-1-yloxy group at position 3.
Cognition Disorders: Disorders characterized by disturbances in mental processes related to learning, thinking, reasoning, and judgment.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Propranolol is a β-adrenergic antagonist commonly used in the treatment of hypertension or acute anxiety." | 5.39 | Propranolol reduces cognitive deficits, amyloid β levels, tau phosphorylation and insulin resistance in response to chronic corticosterone administration. ( Aguirre, N; Dobarro, M; Orejana, L; Ramírez, MJ, 2013) |
| "Propranolol, at a lower dose than that used as antihypertensive (5 mg/kg, 6 wk), attenuated cognitive impairments shown by Tg2576 mice aged 9 months in the novel object recognition and fear conditioning tests." | 1.39 | Propranolol reduces cognitive deficits, amyloid and tau pathology in Alzheimer's transgenic mice. ( Dobarro, M; Gerenu, G; Ramírez, MJ, 2013) |
| "Propranolol is a β-adrenergic antagonist commonly used in the treatment of hypertension or acute anxiety." | 1.39 | Propranolol reduces cognitive deficits, amyloid β levels, tau phosphorylation and insulin resistance in response to chronic corticosterone administration. ( Aguirre, N; Dobarro, M; Orejana, L; Ramírez, MJ, 2013) |
| " In the antipsychotic classification, special attention is given to side effects (extrapyramidal motor signs, tardive dyskinesias, akathisis) and to dosage for the elderly." | 1.25 | Observations on the psychopharmacology of the aged. ( Eisdorfer, C, 1975) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 4 (30.77) | 18.7374 |
| 1990's | 4 (30.77) | 18.2507 |
| 2000's | 2 (15.38) | 29.6817 |
| 2010's | 3 (23.08) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Dobarro, M | 3 |
| Gerenu, G | 1 |
| Ramírez, MJ | 3 |
| Orejana, L | 2 |
| Aguirre, N | 2 |
| Saber, AJ | 1 |
| Cain, DP | 1 |
| Schmidt, JG | 1 |
| Schneider, WN | 1 |
| Schneck, DW | 1 |
| Vieweg, V | 1 |
| Pandurangi, A | 1 |
| Levenson, J | 1 |
| Silverman, J | 1 |
| Helson, L | 1 |
| Duque, L | 1 |
| Eisdorfer, C | 1 |
| Faigel, HC | 1 |
| Jensen, VK | 1 |
| Rogers, TK | 1 |
| Bowman, CE | 1 |
| Wurzelmann, J | 1 |
| Frishman, WH | 1 |
| Aronson, M | 1 |
| Masur, D | 1 |
| Ooi, WL | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Trial of Propranolol in Older Adults With Primary Progressive Aphasia[NCT06066710] | Early Phase 1 | 20 participants (Anticipated) | Interventional | 2024-01-31 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for propranolol and Cognition Disorders
| Article | Year |
|---|---|
The consulting psychiatrist and the polydipsia-hyponatremia syndrome in schizophrenia.
Topics: Angiotensin II; Anti-Inflammatory Agents, Non-Steroidal; Antipsychotic Agents; Carbamazepine; Cognit | 1994 |
12 other studies available for propranolol and Cognition Disorders
| Article | Year |
|---|---|
Propranolol reduces cognitive deficits, amyloid and tau pathology in Alzheimer's transgenic mice.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Amyloid beta-Protein Precursor; Animals; Behavior, Animal; | 2013 |
Propranolol restores cognitive deficits and improves amyloid and Tau pathologies in a senescence-accelerated mouse model.
Topics: Adrenergic beta-Antagonists; Aging; Amyloid Neuropathies; Animals; Antihypertensive Agents; Biomarke | 2013 |
Propranolol reduces cognitive deficits, amyloid β levels, tau phosphorylation and insulin resistance in response to chronic corticosterone administration.
Topics: Adrenergic beta-Antagonists; Amyloid beta-Peptides; Animals; Cognition Disorders; Corticosterone; Di | 2013 |
Combined beta-adrenergic and cholinergic antagonism produces behavioral and cognitive impairments in the water maze: implications for Alzheimer disease and pharmacotherapy with beta-adrenergic antagonists.
Topics: Adrenergic beta-Antagonists; Alzheimer Disease; Analysis of Variance; Animals; Behavior, Animal; Cog | 2003 |
Pharmacologic treatment of cognitive deficits and hypersexuality due to "shaken-baby syndrome".
Topics: Adrenergic beta-Antagonists; Amantadine; Child; Child Behavior Disorders; Cognition Disorders; Dopam | 2000 |
Therapeutic rounds at the Milton S. Hershey Medical Center: central nervous system toxicity caused by lidocaine.
Topics: Cognition Disorders; Confusion; Drug Interactions; Heart Failure; Humans; Lidocaine; Male; Middle Ag | 1983 |
Acute brain syndrome after propranolol.
Topics: Brain; Child; Cognition Disorders; Confusion; Female; Humans; Hypertension; Myoclonus; Propranolol; | 1978 |
Observations on the psychopharmacology of the aged.
Topics: Aged; Amantadine; Antidepressive Agents; Antipsychotic Agents; Basal Ganglia Diseases; Butyrophenone | 1975 |
The effect of beta blockade on stress-induced cognitive dysfunction in adolescents.
Topics: Adolescent; Anxiety; Cognition Disorders; College Admission Test; Female; Humans; Male; Propranolol; | 1991 |
"The effect of beta blockade on stress-induced cognitive dysfunction in adolescents".
Topics: Adolescent; Anxiety; Cognition Disorders; College Admission Test; Humans; Propranolol; Stress, Psych | 1991 |
Cognitive impairment associated with beta-blockade in the elderly.
Topics: Aged; Atenolol; Cognition Disorders; Humans; Male; Propranolol | 1990 |
Neuropsychological effects of antihypertensive drugs.
Topics: Affect; Aged; Aged, 80 and over; Antihypertensive Agents; Cognition Disorders; Depression; Female; H | 1987 |